Clinical characteristics of patients according to PD-L1 gene status
| . | PD-L1 altered (n = 28) . | PD-L1 unaltered (n = 77) . | P . |
|---|---|---|---|
| Age, median (range), y | 62.5 (25-88) | 57 (20-89) | NS |
| Male sex | 57% | 59% | NS |
| Cell of origin | |||
| Non-GCB | 75% | 34% | <.01 |
| GCB | 25% | 53% | .01 |
| Unknown | 0% | 13% | NS |
| Advanced stage | 82% | 53% | <.01 |
| Average LDH | 442 | 308 | .03 |
| Extranodal sites >1 | 54% | 30% | .03 |
| High or high-intermediate IPI | 71% | 31% | <.01 |
| CD30 positive | 44% | 24% | .03 |
| Dual MYC/BCL2 expression | 50% | 41% | NS |
| MYC translocation | 5% | 21% | NS |
| Double-hit lymphoma | 0% | 8% | NS |
| . | PD-L1 altered (n = 28) . | PD-L1 unaltered (n = 77) . | P . |
|---|---|---|---|
| Age, median (range), y | 62.5 (25-88) | 57 (20-89) | NS |
| Male sex | 57% | 59% | NS |
| Cell of origin | |||
| Non-GCB | 75% | 34% | <.01 |
| GCB | 25% | 53% | .01 |
| Unknown | 0% | 13% | NS |
| Advanced stage | 82% | 53% | <.01 |
| Average LDH | 442 | 308 | .03 |
| Extranodal sites >1 | 54% | 30% | .03 |
| High or high-intermediate IPI | 71% | 31% | <.01 |
| CD30 positive | 44% | 24% | .03 |
| Dual MYC/BCL2 expression | 50% | 41% | NS |
| MYC translocation | 5% | 21% | NS |
| Double-hit lymphoma | 0% | 8% | NS |
LDH, lactate dehydrogenase; NS, not significant.